Related Experiment Video
Updated: Aug 21, 2026

Identification of Intracellular Signaling Events Induced in Viable Cells by Interaction with Neighboring Cells Undergoing Apoptotic Cell Death
Published on: December 27, 2016
Sensitization of cells to TRAIL-induced apoptosis by decoy receptor 3
Ying-Yu Wu1, Yung-Chi Chang, Tsui-Ling Hsu
1Institute of Microbiology and Immunology, National Yang-Ming University, Taiwan, Republic of China.
Abstract:
Decoy receptor 3 (DcR3)/TR6/M68 is a soluble receptor that binds to the Fas ligand LIGHT and TL1A. Elevated levels of DcR3 expression have been found in many tumors. We report an unexpected effect of DcR3 by sensitizing Jurkat and U937 cells to apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Cell death triggered by anti-Fas and tumor necrosis factor was unaffected by DcR3. DcR3 by itself did not stimulate apoptosis. The ability to augment TRAIL-initiated cell death was not observed with soluble lymphotoxin beta receptor or soluble death receptor 3, indicating that binding to LIGHT or TL1A alone is insufficient to trigger TRAIL sensitivity. Incubation with DcR3 did not increase the surface expression of TRAIL receptor, and the level of Fas-associated death domain protein and cellular FLICE-like inhibitory protein was not altered. Instead, in the presence of DcR3, TRAIL engagement resulted in an increased activation of caspase-8, an elevated cleavage of Bid, and enhanced release of Smac and cytochrome c from mitochondria to cytosol compared with TRAIL alone. This led to increased activation of caspase-9 and caspase-3. The unusual ability of DcR3 to promote TRAIL-triggered death may be used to potentiate TRAIL efficacy during treatment tumors overexpressing DcR3.
Insights
Decoy receptor 3 (DcR3) unexpectedly sensitizes cancer cells to TRAIL-induced apoptosis. This finding suggests DcR3 could enhance cancer treatments targeting tumors that overexpress it.
Area of Science:
- Immunology
- Molecular Biology
- Cancer Research
Background:
- Decoy receptor 3 (DcR3) is a soluble receptor implicated in various tumors.
- DcR3 binds to Fas ligand LIGHT and TL1A.
Purpose of the Study:
- To investigate the role of DcR3 in apoptosis, particularly in response to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).
Main Methods:
- Utilized Jurkat and U937 cell lines.
- Assessed apoptosis induction by DcR3 in combination with TRAIL, anti-Fas, and tumor necrosis factor.
- Analyzed caspase activation, mitochondrial protein release, and receptor expression.
Main Results:
- DcR3 sensitized cells to TRAIL-induced apoptosis but not to anti-Fas or tumor necrosis factor.
- DcR3 alone did not induce apoptosis.
- Enhanced caspase-8, Bid cleavage, and mitochondrial release of Smac and cytochrome c were observed with DcR3 and TRAIL.
- Increased activation of caspase-9 and caspase-3 was noted.
Conclusions:
- DcR3 potentiates TRAIL-induced apoptosis through caspase activation and mitochondrial pathways.
- DcR3's ability to augment TRAIL sensitivity is specific and not mediated by LIGHT or TL1A binding alone.
- DcR3 may enhance the efficacy of TRAIL-based cancer therapies in tumors overexpressing DcR3.
More Related Videos
Related Concept Videos
The Extrinsic Apoptotic Pathway
GPCR Desensitization
Phagocytosis of Apoptotic Cells
Normal cells contain receptors that prevent them from being recognized by phagocytes.
The Intrinsic Apoptotic Pathway
Apoptosis
Cellular Injury V: Apoptosis and Autophagy

